Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss

One of Ipsen’s flagship oncology assets Cabometyx (cabozantinib) will not be gaining an indication in prostate cancer outside the US or Japan after a Phase III trial failed to meet one of its primary endpoints.